Profil
Michael J.
Chang currently holds the positions of Non-Executive Director at VISEN Pharmaceuticals and Managing Partner at Vivo Capital LLC since 2021.
Mr. Chang earned an MBA from Harvard Business School in 2012 and completed undergraduate studies at Harvard College in 2005.
Postes actifs de Michael Chang
| Sociétés | Poste | Début |
|---|---|---|
| VISEN PHARMACEUTICALS | Directeur/Membre du Conseil | - |
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital invests in both public and private middle market companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceutical, healthcare and life science sectors. It provides financing for early stage, growth stage, buyouts, spin-offs and restructurings. The firm also acquires controlling interest. It acts as lead investor and also makes co-investments. | Private Equity Investor | 01/01/2012 |
Formation de Michael Chang
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Vivo Capital LLC
Vivo Capital LLC Investment ManagersFinance Vivo Capital invests in both public and private middle market companies located across the globe. The firm targets companies operating in the fields of biotechnology, pharmaceutical, healthcare and life science sectors. It provides financing for early stage, growth stage, buyouts, spin-offs and restructurings. The firm also acquires controlling interest. It acts as lead investor and also makes co-investments. | Finance |
Harvard Business School
Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard College
Harvard College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
VISEN Pharmaceuticals
VISEN Pharmaceuticals Pharmaceuticals: MajorHealth Technology Develops, manufactures and commercializes paradigm-shifting endocrine therapies | Health Technology |
















